On December 21, Fang Sheng Pharmaceutical...A product launch and investor relations event for "Yangxue Qufeng Zhitong Granules" was held in Changsha. A representative from Fang Sheng Pharmaceutical stated that Yangxue Qufeng Zhitong Granules is China's first Class 1.1 traditional Chinese medicine specifically formulated for frequent tension-type headaches.Innovative drugsIn June 2025, it obtained the Drug Registration Certificate issued by the National Medical Products Administration. This new drug is derived from the classic formula "Shengxian Decoction" by Zhang Xichun, a famous doctor in modern times. After more than ten years of research and development and clinical trials, it has become the first innovative Chinese medicine in China that is clearly targeted at frequent tension headaches (Qi and Blood Deficiency Syndrome) .

The new product has a large potential market demand.

According to the "Guidelines for the Diagnosis and Treatment of Tension-Type Headache in China" (2023) compiled and released by the Chinese Society of Neurology and the Headache Collaboration Group of the Chinese Society of Neurology, the global prevalence of tension-type headache is 11%-45%, making it the second most common disease globally after dental caries, and also the most common primary headache in my country (accounting for 45.30%). Tension-type headache is a highly prevalent disease in my country with an annual prevalence exceeding 10%, with 285 million patients in 2021.

According to a representative from Fang Sheng Pharmaceutical , current Western medicine treatments for recurrent tension headaches rely on nonsteroidal anti-inflammatory drugs (NSAIDs), which may cause adverse drug reactions in the gastrointestinal tract and kidneys with long-term use. Although the market for traditional Chinese medicine has continued to grow (from 3.9 billion yuan in 2018 to 5.3 billion yuan in 2023), there is a severe shortage of innovative traditional Chinese medicines specifically targeting frequent tension headaches .

According to reports, the research and development of Yangxue Qufeng Zhitong Granules began in 2014, with a total investment of approximately 27 million yuan. It has successively completed Phase II (2014-2018), Phase III (2018-2022) clinical trials and long-term toxicity tests (2023-2024).

The aforementioned person in charge stated that the Nourishing Blood, Dispelling Wind, and Relieving Pain Granules follow the traditional Chinese medicine principle of "treating the symptoms in acute cases and addressing the root cause in chronic cases." It can quickly relieve short-term headache symptoms and effectively reduce the frequency of headache attacks, achieving a balance between short-term efficacy and long-term conditioning. Furthermore, the ingredients do not contain toxic medicinal materials, making it highly safe and meeting the needs of long-term management of chronic diseases.

Strengthen the strategic layout of innovative traditional Chinese medicine drugs

New drug development capability is a core competitive advantage that Fang Sheng Pharmaceutical has established and continuously built since its inception. In recent years, the company has continued to focus on its main business, increased its R&D investment, significantly improved the speed and efficiency of R&D for innovative traditional Chinese medicines, and promoted the approval, launch and commercialization of innovative traditional Chinese medicines such as Xiaojingxing Zhike Granules for Children and Xuanqi Jian Gu Tablets.

As an innovative traditional Chinese medicine for neurological diseases, the approval of Yangxue Qufeng Zhitong Granules further enriches Fang Sheng Pharmaceutical's pipeline of innovative traditional Chinese medicine products, strengthens its comprehensive competitiveness of "a multi-product matrix with innovative traditional Chinese medicine as the core", and is conducive to the company's accelerated implementation of the development strategy of "building a health industry group with innovative traditional Chinese medicine as the core". It is expected to continuously improve the company's overall profitability.

Reporters learned that Fang Sheng Pharmaceutical has been deeply involved in drug research and development for more than 20 years, consistently adhering to and dedicating itself to the highly challenging and long-term path of traditional Chinese medicine innovation, and is now entering a period of fruitful results. In the past 10 years, 32 Class 1.1 innovative traditional Chinese medicines have been approved nationwide, while only 4 innovative traditional Chinese medicines have been approved for marketing in Hunan Province, 3 of which belong to Fang Sheng Pharmaceutical.

To date, Fang Sheng Pharmaceutical has nearly 20 innovative traditional Chinese medicine (TCM) projects progressing smoothly. Among them, three Class 1.1 new TCM drugs, including Xiangqin Antipyretic Granules and Ziying Granules, have entered the clinical trial stage, covering multiple fields such as respiratory system and gynecology. Simultaneously, Fang Sheng Pharmaceutical is actively expanding into cutting-edge fields, collaborating with top research institutions such as China Pharmaceutical University and the Institute of Materia Medica, Chinese Academy of Medical Sciences, and acquiring Class 1 innovative chemical drug projects. It is gradually building a diversified product matrix with "TCM innovative drugs as the mainstay, chemical drugs as a supplement, and cutting-edge innovative drugs as a component," providing ample momentum for the company's continued development.

https://finance.eastmoney.com/a/202512223598218034.html